Let’s Chat About … Opus Genetics

Ben Yerxa, PhD, is Co-Founder & President of Opus Genetics. Founded in 2021, Opus Genetics is a patient-first, science-driven gene therapy company tackling manufacturing obstacles standing in the way of treatments for ultra-rare blinding conditions. Dr. Yerxa will speak about the Opus Genetics’ business model, pipeline, manufacturing process, and their focus on tried and true methods.

About Benjamin Yerxa, PhD
Foundation Fighting Blindness

As its Chief Executive Officer, Dr. Yerxa is responsible for the overall management of the Foundation Fighting Blindness, the world’s leading private funder of research on potential treatments and cures for inherited retinal degenerative diseases including age-related macular degeneration. He also serves as CEO of the Retinal Degeneration Fund, a wholly owned, not-for-profit subsidiary focused on making venture philanthropy investments to further the Foundation’s mission. Dr. Yerxa has more than 25 years’ experience in biotechnology, drug development, and in translating promising research discoveries into clinical milestones and treatments. His experience, from drug discovery through product launches and in leadership positions, is in the pulmonary, oral health, cardiovascular, HIV, and ophthalmology fields. Just before joining the Foundation, Dr. Yerxa was president and co-founder of Envisia Therapeutics, a company focused on developing novel ocular sustained delivery therapies for the front and back of the eye. Dr. Yerxa holds 60 U.S. patents. An inventor of DIQUAS™, an innovative treatment for dry eye approved in Japan, he has been involved in the discovery and development of investigational new drugs, Phase 3 clinical programs, new drug applications, and drug approvals. Dr. Yerxa earned his PhD in organic chemistry from University of California, Irvine, and BA in chemistry from the University of California, San Diego.

Hope in Focus is proud to bring our web series “Let’s Chat About …” to the Leber congenital amaurosis and rare inherited retinal disease communities. We’ve developed the series with those living with LCA and IRDs in mind, but we invite all members of our community, including those in research, industry, and the regulatory communities to join any of the sessions, as we look ahead to a common goal of advancing treatments for rare retinal disease.